logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Complicated Intraabdominal Infection

    FiltersReset Filters
    5 results

    • avycaz

      (ceftazidime, avibactam)
      Allergan, Inc.
      Usage: AVYCAZ (ceftazidime and avibactam) is indicated for treating complicated intra-abdominal and urinary tract infections, including pyelonephritis, as well as hospital-acquired and ventilator-associated bacterial pneumonia. It targets susceptible gram-negative bacteria in adult and pediatric patients (≥31 weeks gestational age).

    • ciprofloxacin

      (Ciprofloxacin Tablets)
      Yiling Pharmaceutical, Inc.
      Usage: Ciprofloxacin tablets are indicated for the treatment of various infections in adults, including skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, infectious diarrhea, typhoid fever, gonorrhea, inhalational anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections, and urinary tract infections.

    • recarbrio

      (imipenem anhydrous, cilastatin, and relebactam anhydrous)
      Merck Sharp & Dohme LLC
      Usage: RECARBRIO™ is indicated for treating hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, complicated urinary tract infections (cUTI), and complicated intra-abdominal infections (cIAI) in adults aged 18 and older, caused by specific susceptible gram-negative microorganisms. Usage should be guided by susceptibility data to reduce drug resistance.

    • xerava

      (eravacycline)
      Tetraphase Pharmaceuticals, Inc.
      Usage: XERAVA is indicated for treating complicated intra-abdominal infections (cIAI) in adults caused by specific susceptible microorganisms. It is not approved for complicated urinary tract infections (cUTI). Its use should aim to reduce drug-resistant bacteria, basing treatment on culture results and local susceptibility patterns.

    • zerbaxa

      (ceftolozane and tazobactam)
      Merck Sharp & Dohme LLC
      Usage: ZERBAXA is indicated for the treatment of complicated intra-abdominal infections, complicated urinary tract infections (including pyelonephritis), and hospital-acquired or ventilator-associated bacterial pneumonia in adults and pediatric patients, targeting specific susceptible Gram-negative and Gram-positive bacteria. Usage should be guided by culture results and epidemiology.